Related Experiment Videos

The accumulation of [35S]methimazole by human and rat lymphocytes

Acta Endocrinologica
|January 1, 1983
PubMed

Insights

Methimazole (MMI) does not accumulate significantly in lymphocytes of patients with Graves' disease. This suggests methimazole

Area of Science:

  • Endocrinology
  • Immunology
  • Pharmacology

Background:

  • Graves' disease is an autoimmune disorder affecting the thyroid.
  • Methimazole (MMI) is a common antithyroid drug used to treat hyperthyroidism.
  • The mechanism of MMI's immunosuppressive action on lymphocytes is not fully understood.

Purpose of the Study:

  • To investigate the accumulation of radiolabeled methimazole (MMI) in lymphocytes.
  • To determine if MMI directly affects lymphocyte function in Graves' disease patients.

Main Methods:

  • In vitro incubation of peripheral blood lymphocytes (PBL) with [35S]MMI in normal subjects.
  • Administration of [35S]MMI to Graves' hyperthyroidism patients and measurement of 35S activity in PBL and thyroid lymphocytes.
  • Administration of [35S]MMI to normal rats and rats with experimental autoimmune thyroiditis.

Main Results:

  • No [35S]MMI uptake was observed in PBL from normal controls in vitro.
  • Elevated PBL to plasma 35S activity ratios were found in a subset of Graves' disease patients.
  • Some 35S accumulation was detected in thyroid lymphocytes of two patients.
  • No significant [35S]MMI accumulation was found in lymphocytes of rats, even those with experimental autoimmune thyroiditis.

Conclusions:

  • Methimazole (MMI) shows minimal to no significant accumulation in lymphocytes of Graves' disease patients.
  • The immunosuppressive effects of MMI on lymphocyte antibody production are likely indirect.
  • Further research is needed to elucidate the indirect mechanisms of MMI's immunomodulatory actions.

Related Concept Videos